Shire

Shire acquires Pervasis’ assets

Monday, April 16, 2012 09:47 AM

Shire Pharmaceuticals, a global specialty biopharmaceutical company, will acquire all the assets of Pervasis Therapeutics of Cambridge, Mass.

More... »

Shire to license CNS disorder drug worldwide

Wednesday, March 21, 2012 10:36 AM

Heptares Therapeutics, a U.K.-based drug discovery company, has granted Shire Pharmaceuticals, the global specialty biopharmaceutical company, exclusive worldwide license of novel adenosine A2A antagonist for central nervous system disorders, currently in preclinical development.

More... »

Shire to acquire FerroKin BioSciences and phase II iron chelator treatment

Friday, March 16, 2012 01:07 PM

Shire, the global specialty biopharmaceutical company, has signed an agreement to acquire San Carlos, Calif.-based FerroKin BioSciences for an upfront payment of $100 million.

More... »

Shire and arGEN-X enter therapeutic antibody alliance

Wednesday, February 29, 2012 04:12 PM

Netherlands-based arGEN-X has entered into an alliance with U.K.-based Shire Pharmaceuticals to create novel therapeutic antibody products against multiple targets submitted by the latter.

More... »

Sangart appoints three to leadership team

Friday, February 17, 2012 12:43 PM

Sangart, a privately held biopharmaceutical company focused on oxygen-therapeutic agents, has appointed three new members to its executive team.

More... »

Vyvanse capsules approved to treat adults with ADHD

Friday, February 10, 2012 12:08 PM

The FDA has approved Vyvanse (lisdexamfetamine dimesylate) capsules as a maintenance treatment for adults with ADHD, according to Shire Pharmaceuticals, a global specialty biopharmaceutical company.

More... »

The CenterWatch Monthly, February 2012

Friday, February 3, 2012 12:01 PM

Anticipating the rise of virtual drug development

More... »

Shire and Sangamo join to combat monogenic diseases

Wednesday, February 1, 2012 03:34 PM

Shire, a global specialty biopharmaceutical company, and Sangamo BioSciences, which offers genome-editing technology, have signed a collaboration and license agreement to develop therapeutics for hemophilia and other monogenic diseases based on Sangamo's zinc finger DNA-binding protein (ZFP) technology.

More... »

ICON named sole provider of central lab services to Shire

Monday, January 9, 2012 01:45 PM

CRO ICON has signed a strategic partnership with Shire Specialty Pharmaceuticals to serve as the sole global provider of central laboratory services and one of two strategic partners for clinical development services.

More... »

Shire partners with Shionogi to develop ADHD medicines

Friday, November 18, 2011 11:48 AM

Shire has entered into an agreement with Shionogi & Co. of Japan to co-develop and co-commercialize certain of Shire's Attention Deficit Hyperactivity Disorder (ADHD) medicines in Japan. Shionogi will pay a one time fee and share costs with Shire in exchange for rights to jointly co-develop and co-commercialize the products upon approval for the Japanese market. Specific terms of the agreement are not being disclosed. 

More... »